Acute acalculous cholecystitis following extended administration of nirmatrelvir/ritonavir for persistent SARS-CoV-2 infection

• Published in: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy Vol. 30; no. 7; pp. 659 - 663
• Main Authors: Ito, Wataru, Fukumori, Tatsuya, Asaoka, Nao, Imakita, Natsuko, Nishimura, Tomoko, Furukawa, Ryutaro, Nishihara, Yuji, Fujikura, Hiroyuki, Sekine, Takahiro, Yamaguchi, Naoki, Hirata, Yuichiro, Miyamoto, Sho, Kanno, Takayuki, Katano, Harutaka, Suzuki, Tadaki, Kasahara, Kei
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.07.2024
• Subjects: Acalculous Cholecystitis - chemically induced; Acalculous Cholecystitis - drug therapy; Acalculous Cholecystitis - virology; Acute acalculous cholecystitis; Aged; Alanine - administration & dosage; Alanine - adverse effects; Alanine - analogs & derivatives; Alanine - therapeutic use; Antibodies, Monoclonal, Humanized; Antiviral Agents - administration & dosage; Antiviral Agents - therapeutic use; COVID-19 - complications; COVID-19 Drug Treatment; Gamma-glutamyl transpeptidase; Humans; Immunocompromised Host; Lymphoma; Lymphoma, Follicular - drug therapy; Male; Nirmatrelvir/ritonavir; Obinutuzumab; Persistent SARS-CoV-2 infection; Ritonavir - administration & dosage; Ritonavir - adverse effects; Ritonavir - therapeutic use; SARS-CoV-2; Persistent SARS-CoV-2 infection; Obinutuzumab; Nirmatrelvir/ritonavir; Acute acalculous cholecystitis; Gamma-glutamyl transpeptidase; Lymphoma

Immunocompromised patients with hematologic malignancies, particularly those treated with anti-CD20 antibodies such as rituximab and obinutuzumab, are known to be at risk of prolonged infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Prolonged administration or combination...